Device Trial Radar · NCT05829083
DUET Versus Standard Interface for Hypercapnic COPD Patients
Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jul 18, 2023
Primary completion
Dec 1, 2025
Study completion Dec 1, 2025
Sponsor
- Lead sponsor
- Larissa University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sotiria General Hospital
- First posted
- Apr 25, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to compare the new asymmetric nasal high flow interface with the conventional high flow nasal cannula in patients with COPD exacerbation. The main questions the study aims to answer are: • Does the use of the asymmetric interface lead to: 1. A greater decrease in the patients' carbon dioxide 2. A greater decrease in respiratory rate and less dyspnea 3. Less need for advanced oxygen therapy measures 4. Same tolerance and comfort 5. Lower heart rate and blood pressure Participants will be asked to: Wear the asymmetric and conventional cannulas for 3 hours each with a 30 minute gap in-between. Arterial blood samples and various clinical parameters will be collected throughout the study period. Researchers will compare the effect of asymmetric versus conventional cannulas to answer the aforementioned questions.
Conditions
- COPD Exacerbation
- Hypercapnia
- COPD
Interventions
Asymmetric nasal cannula - DUETDevice
DUET asymmetric nasal high flow interface that fits best to the patients' nostrils (size: one nostril of the patient should be fully occluded) Patients will be crossed-over between the 2 interventions
Conventional nasal high flow cannulaDevice
Well-established conventional nasal high flow cannula (size: medium) Patients will be crossed-over between the 2 interventions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arterial PCO2Time frame: Immediately before and after the application of 3 hours of nasal high flow therapy (3 hours for each cannula type)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sotiria General Hospital
Athens, Greece · Recruiting
University Hospital of Larissa
Larissa, Greece · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.